Human iPSC-derived Hepatocytes ReproHepateTM for CYP Assay and Drug Toxicity Testing
Poster Mar 20, 2015
Annand R; Akahira R; Tamura K; Inamura M
Pharmaceutical candidate compounds require extended period of time and large amount of development costs before reaching the market. However, for various reasons, most of the candidates will be canceled in their development process. One major reason is hepatotoxicity. Recently, in the beginning of the drug screening process, simple and fast evaluation using cell-based assays has been given great importance in terms of safety and cost reduction. Although human primary hepatocytes have been widely used for hepatotoxicity, problems still remain: lot-to-lot variation, commercial availability and unstable supply. Moreover, there is a great difficulty in executing long-term tests using hepatocytes from the identical donor.
Human-derived iPS cells are pluripotent stem cells with the ability of infinite proliferation and differentiation into various cells including hepatocytes. Therefore, iPS cells enable unlimited production of hepatocytes possessing the same genetic back ground. Furthermore, it is possible to produce various donor-derived hepatocytes since human derived iPS cells can be establish from varied race, sex and genetic back ground.
Quantitative Live-Cell Analysis Using Automated Long-Term ImagingPoster
Here we describe a continuous live-cell assay for determining cell proliferation profiles using the BioSpa Automated Live Cell Imaging System, consisting of BioSpa 8 and Cytation 5.READ MORE
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE